Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: Pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies

Murielle Mimeault, Surinder Kumar Batra

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Complex signaling cross-talks between different growth factor cascades orchestrate the primary brain cancer development. Among the frequent deregulated oncogenic pathways, the ligand-activated wild-type epidermal growth factor receptor (EGFR), constitutively activated EGFRvIII mutant and sonic hedgehog pathways have attracted much attention because of their pivotal roles in pediatric medulloblastomas and adult glioblastoma multiformes (GBM) brain tumors. The enhanced expression levels and activation of EGFR, EGFRvIII mutant and hedgehog signaling elements can provide key roles for the sustained growth, migration and local invasion of brain tumor-initiating cells (BTICs) and their progenies, resistance to current therapies and disease relapse. These tumorigenic cascades also can cooperate with Wnt/β-catenin, Notch, platelet-derived growth factor (PDGF)/PDGF receptors (PDGFRs), hepatocyte growth factor (HGF)/c-Met receptor and vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFRs) for the acquisition of a more malignant behavior and survival advantages by brain tumor cells during disease progression. Therefore, the simultaneous targeting of these oncogenic signaling components including wild-type EGFR, EGFRvIII mutant and hedgehog pathways may constitute a potential therapeutic approach of great clinical interest to eradicate BTICs and improve the efficacy of current clinical treatments by radiation and/or chemotherapy against aggressive and recurrent medulloblastomas and GBMs.

Original languageEnglish (US)
Pages (from-to)479-500
Number of pages22
JournalBrain Pathology
Volume21
Issue number5
DOIs
StatePublished - Sep 1 2011

Fingerprint

Neoplastic Stem Cells
Epidermal Growth Factor Receptor
Brain Neoplasms
Vascular Endothelial Growth Factor Receptor
Medulloblastoma
Therapeutics
Platelet-Derived Growth Factor Receptors
Catenins
Hepatocyte Growth Factor
Platelet-Derived Growth Factor
Glioblastoma
Disease Progression
Intercellular Signaling Peptides and Proteins
epidermal growth factor receptor VIII
Radiation
Pediatrics
Ligands
Recurrence
Drug Therapy
Growth

Keywords

  • EGFR
  • EGFRvIII
  • brain tumor-initiating cells
  • carcinogenesis
  • combination therapy
  • glioblastoma multiforme
  • hedgehog
  • medulloblastomas
  • molecular targeting
  • receptor tyrosine kinases

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neuroscience(all)
  • Clinical Neurology

Cite this

@article{adf1cc0c53974f5f8165f3a324aa6972,
title = "Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: Pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies",
abstract = "Complex signaling cross-talks between different growth factor cascades orchestrate the primary brain cancer development. Among the frequent deregulated oncogenic pathways, the ligand-activated wild-type epidermal growth factor receptor (EGFR), constitutively activated EGFRvIII mutant and sonic hedgehog pathways have attracted much attention because of their pivotal roles in pediatric medulloblastomas and adult glioblastoma multiformes (GBM) brain tumors. The enhanced expression levels and activation of EGFR, EGFRvIII mutant and hedgehog signaling elements can provide key roles for the sustained growth, migration and local invasion of brain tumor-initiating cells (BTICs) and their progenies, resistance to current therapies and disease relapse. These tumorigenic cascades also can cooperate with Wnt/β-catenin, Notch, platelet-derived growth factor (PDGF)/PDGF receptors (PDGFRs), hepatocyte growth factor (HGF)/c-Met receptor and vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFRs) for the acquisition of a more malignant behavior and survival advantages by brain tumor cells during disease progression. Therefore, the simultaneous targeting of these oncogenic signaling components including wild-type EGFR, EGFRvIII mutant and hedgehog pathways may constitute a potential therapeutic approach of great clinical interest to eradicate BTICs and improve the efficacy of current clinical treatments by radiation and/or chemotherapy against aggressive and recurrent medulloblastomas and GBMs.",
keywords = "EGFR, EGFRvIII, brain tumor-initiating cells, carcinogenesis, combination therapy, glioblastoma multiforme, hedgehog, medulloblastomas, molecular targeting, receptor tyrosine kinases",
author = "Murielle Mimeault and Batra, {Surinder Kumar}",
year = "2011",
month = "9",
day = "1",
doi = "10.1111/j.1750-3639.2011.00505.x",
language = "English (US)",
volume = "21",
pages = "479--500",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies

T2 - Pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies

AU - Mimeault, Murielle

AU - Batra, Surinder Kumar

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Complex signaling cross-talks between different growth factor cascades orchestrate the primary brain cancer development. Among the frequent deregulated oncogenic pathways, the ligand-activated wild-type epidermal growth factor receptor (EGFR), constitutively activated EGFRvIII mutant and sonic hedgehog pathways have attracted much attention because of their pivotal roles in pediatric medulloblastomas and adult glioblastoma multiformes (GBM) brain tumors. The enhanced expression levels and activation of EGFR, EGFRvIII mutant and hedgehog signaling elements can provide key roles for the sustained growth, migration and local invasion of brain tumor-initiating cells (BTICs) and their progenies, resistance to current therapies and disease relapse. These tumorigenic cascades also can cooperate with Wnt/β-catenin, Notch, platelet-derived growth factor (PDGF)/PDGF receptors (PDGFRs), hepatocyte growth factor (HGF)/c-Met receptor and vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFRs) for the acquisition of a more malignant behavior and survival advantages by brain tumor cells during disease progression. Therefore, the simultaneous targeting of these oncogenic signaling components including wild-type EGFR, EGFRvIII mutant and hedgehog pathways may constitute a potential therapeutic approach of great clinical interest to eradicate BTICs and improve the efficacy of current clinical treatments by radiation and/or chemotherapy against aggressive and recurrent medulloblastomas and GBMs.

AB - Complex signaling cross-talks between different growth factor cascades orchestrate the primary brain cancer development. Among the frequent deregulated oncogenic pathways, the ligand-activated wild-type epidermal growth factor receptor (EGFR), constitutively activated EGFRvIII mutant and sonic hedgehog pathways have attracted much attention because of their pivotal roles in pediatric medulloblastomas and adult glioblastoma multiformes (GBM) brain tumors. The enhanced expression levels and activation of EGFR, EGFRvIII mutant and hedgehog signaling elements can provide key roles for the sustained growth, migration and local invasion of brain tumor-initiating cells (BTICs) and their progenies, resistance to current therapies and disease relapse. These tumorigenic cascades also can cooperate with Wnt/β-catenin, Notch, platelet-derived growth factor (PDGF)/PDGF receptors (PDGFRs), hepatocyte growth factor (HGF)/c-Met receptor and vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFRs) for the acquisition of a more malignant behavior and survival advantages by brain tumor cells during disease progression. Therefore, the simultaneous targeting of these oncogenic signaling components including wild-type EGFR, EGFRvIII mutant and hedgehog pathways may constitute a potential therapeutic approach of great clinical interest to eradicate BTICs and improve the efficacy of current clinical treatments by radiation and/or chemotherapy against aggressive and recurrent medulloblastomas and GBMs.

KW - EGFR

KW - EGFRvIII

KW - brain tumor-initiating cells

KW - carcinogenesis

KW - combination therapy

KW - glioblastoma multiforme

KW - hedgehog

KW - medulloblastomas

KW - molecular targeting

KW - receptor tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=80052023181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052023181&partnerID=8YFLogxK

U2 - 10.1111/j.1750-3639.2011.00505.x

DO - 10.1111/j.1750-3639.2011.00505.x

M3 - Review article

C2 - 21615592

AN - SCOPUS:80052023181

VL - 21

SP - 479

EP - 500

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

IS - 5

ER -